Meet Redsense Medical at the Swiss Nordic Bio 2024

Redsense Medical CEO Pontus Nobréus will present at the Swiss Nordic Bio in Zürich on March 7, 2024.

Swiss Nordic Bio in Zurich is a high-level partnering and investor event where Swiss and Nordic biotech and healthtech startups, pharmaceutical companies and investors meet. Swiss Nordic Bio carries 17 years of tradition, previously Swiss Scandinavian Bio-Business Seminar, and is organised by the Nordic countries in cooperation with Swiss partners.

For further information about the event, please visit: swissnordicbio.com

Contact information

For more information, please contact: 
Pontus Nobréus, CEO
Telephone: +46 72-171 1264
E-mail: pontus.nobreus (at) redsensemedical.com

Redsense Medical AB (publ), 556646-4862

ABOUT REDSENSE MEDICAL

Redsense Medical is a corporate group with operations mainly in Europe and the United States. The company has developed the Redsense System, an innovation used for monitoring and alarm in the case of blood leakage in connection with a hemodialysis treatment. Redsense Medical solves one of the most serious remaining safety problems within hemodialysis – to quickly detect Venous Needle Dislodgement and catheter leakage to minimize blood leakage. The system consists of a patented fiber optic sensor, designed for either venous needle or central venous catheter, which is connected to an alarm unit. From the very start, the development of the company's technology has been based on the demands and safety requirements of healthcare providers in the dialysis sector. The Redsense Medical share is listed on Spotlight Stock Market (REDS) and traded on OTCQX (RDSNF) in the US.